NGS-based virus testing, a preferred approach to mitigating the virus contamination risk
While advanced therapy medicinal products (ATMPs) represent a promising new generation of treatments, they are more vulnerable to viral contaminations that could go undetected by standard methods compared to well-established biologics such as monoclonal antibodies.
Next generation sequencing (NGS) is not new but has recently started to gain more recognition as an advanced technology for viral safety testing of biologics. In this recent article published in BioProcess Journal, learn more about NGS and how it has the potential to replace several different established testing methods for ATMPs with improved turnaround times and reduced overall costs.